Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Theravance Biopharma's EBIT per Share for the
three
months ended in Mar. 2026 was $-0.13.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $2.67.
During the past 3 years, the average EBIT per Share Growth Rate was 59.80% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 51.50% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 27.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Theravance Biopharma's EBIT per Share or its related term are showing as below:
TBPH'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -161.7 Med: 8.2 Max: 59.8
Current: 59.8
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Theravance Biopharma was 59.80% per year. The lowest was -161.70% per year. And the median was 8.20% per year.
TBPH's 3-Year EBIT Growth Rate is ranked better than 90.78% of 1172
companies
in the Biotechnology industry
Industry Median: 15.5
vs TBPH: 59.80
Theravance Biopharma (NAS:TBPH) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Theravance Biopharma EBIT per Share Related Terms
Theravance Biopharma EBIT per Share Historical Data
* Premium members only.
The historical data trend for Theravance Biopharma's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.67
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Theravance Biopharma (TBPH) has a EBIT per Share of $2.67 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Theravance Biopharma and its competitors. According to the industry distribution chart, Theravance Biopharma ranks #108 out of 1172 companies in the Biotechnology industry, placing it in the top 9.2%.
Is Theravance Biopharma's EBIT per Share too high?
Theravance Biopharma's current EBIT per Share is $2.67. The Biotechnology industry median EBIT per Share is 15.50. Theravance Biopharma's value of $2.67 is 82.8% below this industry median. Based on the distribution chart, Theravance Biopharma ranks #108 out of 1172 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Theravance Biopharma has a GF Score™ of 72/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Theravance Biopharma's EBIT per Share compare to ABUS and SANA?
According to the Biotechnology industry distribution chart, Theravance Biopharma ranks #108 out of 1172 companies for EBIT per Share. This places Theravance Biopharma in the top 9% of its industry — outperforming the majority of peers. The industry median EBIT per Share is 15.50. Theravance Biopharma's value of $2.67 is 82.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.50, based on 1,172 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Theravance Biopharma's current EBIT per Share of $2.67 is 82.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Theravance Biopharma and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Theravance Biopharma's current EBIT per Share is $2.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Theravance Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Theravance Biopharma (TBPH) is currently considered Modestly Undervalued. The stock's GF Value™ is $18.67, compared to a current price of $16.86 — trading 9.7% below its estimated fair value. The current EBIT per Share is $2.67 and 82.8% below the Biotechnology industry median of 15.50. Theravance Biopharma's overall GF Score™ is 72/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Theravance Biopharma (TBPH), the current EBIT per Share is $2.67 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Theravance Biopharma (TBPH) Overvalued in 2026?
Based on GuruFocus' analysis, Theravance Biopharma stock appears to be undervalued.
The current stock price of $16.86 is trading 9.7% below its estimated GF Value™ of $18.67.
GuruFocus considers Theravance Biopharma to be Modestly Undervalued.
Key valuation signals for TBPH:
EBIT per Share: $2.67
GF Value™: $18.67 vs. price of $16.86 (9.7% below fair value)
Industry Position: 82.8% below the Biotechnology median (#108 of 1172)
No single metric tells the full story. See the TBPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.
72GF Score
Get the complete analysis for TBPH
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TBPH has been successfully added to your 
